6 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 6, Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Hemophilia: new trials by email Literature Review of Hemophilia trials Research Report on Hemophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) - Hemophilia | Phase 3 | Recruiting | Sanofi | 85 | 2025-12-18 | 2026-10-27 |
| Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients STSP-0601 for Injection - Hemophilia | Phase 3 | Active not recruiting | Jiangsu BioJeTay Biotechnology Co., Ltd. | 40 | 2025-03-26 | 2026-08-12 |
| Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery Coagulation Factor VIIa (Recombinant) - Hemophilia | Phase 3 | Terminated | Laboratoire français de Fractionnement et de Biotechnologies | 2 | 2024-06-07 | 2026-07-31 |
| A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) - Hemophilia | Phase 3 | Active not recruiting | Sanofi | 91 | 2023-02-01 | 2026-02-04 |
| Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B Fitusiran - Hemophilia | Phase 2 / Phase 3 | Completed | Genzyme, a Sanofi Company | 32 | 2020-01-28 | 2026-09-28 |
| Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX Fitusiran - Hemophilia | Phase 3 | Completed | Genzyme, a Sanofi Company | 281 | 2019-01-09 | 2026-09-30 |
| A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis Fitusiran, BPA prophylaxis, Factor (FVIII or FIX) prophylaxis - Hemophilia | Phase 3 | Completed | Genzyme, a Sanofi Company | 80 | 2018-07-25 | 2023-02-06 |
| LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures Coagulation Factor VIIa (Recombinant) - Hemophilia | Phase 3 | Completed | Laboratoire français de Fractionnement et de Biotechnologies | 12 | 2016-08-25 | 2022-02-25 |
| Prospective Biomarkers of Bone Metabolism in Hemophilia A Advate - Hemophilia, Bone Disease | Phase 3 | Completed | Oregon Health and Science University | 16 | 2014-12-01 | 2020-04-01 |
| BAY14-2222 Continuous Infusion in Surgeries Kogenate (BAY14-2222) - Hemophilia | Phase 3 | Completed | Bayer | 15 | 2004-07-01 | 2010-04-13 |
Hemophilia A (10) · Bone Diseases (1)
Blood Coagulation Disorders (10) · Blood Coagulation Disorders, Inherited (10) · Coagulation Protein Disorders (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Hemorrhagic Disorders (10) · Musculoskeletal Diseases (1)
fitusiran (5) · Factor VII (2) · BAY 14-2222 (1) · F8 protein, human (1) · Factor VIII (1) · Injections (1)
Genzyme, a Sanofi Company (3) · Laboratoire français de Fractionnement et de Biotechnologies (2) · Sanofi (2) · Bayer (1) · Jiangsu BioJeTay Biotechnology Co., Ltd. (1) · Oregon Health and Science University (1)
United States (8) · Turkey (Türkiye) (6) · China (5) · Italy (5) · Canada (4) · India (4) · Mexico (4) · South Africa (4) · Spain (4) · France (3) · Israel (3) · Japan (3) · Malaysia (3) · South Korea (3) · Taiwan (3)
Jason Taylor, MD, PhD (1) · Lei Zhang, Ph.D (1) · Miguel Escobar, MD (1)
2016 (1), 2018 (1), 2019 (1), 2023 (1), 2025 (1)